Beta-Sheet Breaker Peptide iAβ5 (C33H43N5O8), with the sequence H-Leu-Pro-Phe-Phe-Asp-OH, has been shown to inhibit amyloidogenesis in rat brain models. Research showed that beta-sheet breaker peptide significantly reduces amyloid beta-protein deposition in vivo and completely blocks the formation of amyloid fibrils in a rat brain model of amyloidosis. Current evidence supports the notion that beta-amyloid deposits or Abeta intermediates may be responsible for the pathogenesis in Alzheimer’s disease (AD) patients. Because of its inhibition of cerebral amyloid beta-protein deposition, Beta-Sheet Breaker Peptide seems to be an important target for Alzheimer's disease therapy.
References:
1. C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castano, and B. Frangione, Nat. Med., 4, 822 (1998) (Original; Pharmacol.)
2. MA Chacon, MI Barria, C Soto and NC Inestrosa. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits.